SS Innovations International (NASDAQ: SSII) has reported substantial growth in the adoption and utilization of its SSi Mantra surgical robotic system, according to a recent press release. As of September 8, 2026, the company has completed 14,103 cumulative procedures, a 79% increase from 7,885 at the end of 2025. The installed base of SSi Mantra systems has also risen by 42%, reaching 238 units across 12 countries, up from 168 systems previously.
The expansion reflects a broader trend in healthcare toward robotic-assisted surgery, which offers potential benefits such as smaller incisions, reduced pain, and faster recovery times. SS Innovations has trained approximately 1,500 physicians on the platform, which has been used for more than 170 types of surgical procedures, indicating its versatility and growing acceptance among surgeons worldwide.
Recent international milestones underscore the company's global reach. Robotic cardiac surgery was launched in Colombia, the first SSi Mantra was installed in Sri Lanka, and the first telesurgery was performed within the Philippines. Additionally, SS Innovations highlighted 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of August 31, including a remarkable telesurgery conducted over a distance of more than 13,600 miles between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India, demonstrating the system's efficiency and reliability.
Looking ahead, SS Innovations anticipates that the U.S. Food and Drug Administration will complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. The company also believes it can obtain European Union CE marking certification by year-end 2026. These regulatory milestones are critical for market expansion into two of the world's largest healthcare markets, potentially opening significant new revenue streams and further validating the technology's safety and efficacy.
The company's vision is to make robotic surgery affordable and accessible to a larger segment of the global population. Its product range includes the SSi Mantra system and the comprehensive suite of SSi Mudra surgical instruments, which support various procedures, including cardiac surgery. An American company headquartered in India, SS Innovations aims to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
For more details, the full report is available at https://ibn.fm/DJILj. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.
